Literature DB >> 18206113

Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases.

Takamitsu Nakano1, Katsuyuki Nakajima, Manabu Niimi, Masaki Q Fujita, Yasuhiro Nakajima, Sanae Takeichi, Makoto Kinoshita, Teruhiko Matsushima, Tamio Teramoto, Akira Tanaka.   

Abstract

BACKGROUND: ApoB-48 is a major apolipoprotein secreted by the small intestine and is the main constitutive apolipoprotein in chylomicrons (CM). In the past, presence of apoB-48 in human aortic atherosclerotic plaques has not been detected.
METHODS: A newly developed apoB-48 ELISA together with an HPLC fractionation technique, were applied to investigate the presence of apoB-48 (CM) in aortic atherosclerotic plaques. The atherosclerotic plaques were obtained from aortae of sudden cardiac death cases. Total cholesterol, triglycerides (TG), apoB-100 and apoB-48 were measured in the aortic plaques extracts.
RESULTS: HPLC analysis of plaques extracts monitored by cholesterol revealed mainly particle sizes of CM and very low density lipoproteins (VLDL) in the d>1.006 fractions. The plaques extracts were monitored by apoB-48 and apoB-100 ELISA. There were no TG peaks in any lipoprotein fraction extracted from the plaques except as free glycerol. ApoB-100 was detected in VLDL particles and in LDL sizes. In contrast, apoB-48 was detected in particles of CM, VLDL and LDL sizes. Further, in postmortem plasma, apo B-48 was detected in particles sizes of HDL or smaller and the Western blot analysis could not show any 250 kDa molecular weight (MW) protein in the plaque extracts, but smaller and broader MW staining were observed at 20-150 kDa.
CONCLUSION: Hitherto there has been lack of an appropriate assay to measure apoB-48 in plaques. Our investigations show that apoB-48 is present in atherosclerotic plaques with denatured or degraded structure. This is the first report describing presence of apoB-48 in human atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18206113     DOI: 10.1016/j.cca.2007.12.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  22 in total

1.  Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.

Authors:  Yutaka Mori; Genshin Kuriyama; Takaaki Tanaka; Naoko Tajima
Journal:  Endocrine       Date:  2009-10-16       Impact factor: 3.633

Review 2.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

Review 3.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

4.  Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Authors:  Adam E Mullick; Wuxia Fu; Mark J Graham; Richard G Lee; Donna Witchell; Thomas A Bell; Charles P Whipple; Rosanne M Crooke
Journal:  J Lipid Res       Date:  2011-02-22       Impact factor: 5.922

Review 5.  Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Authors:  Bai-Hui Zhang; Fan Yin; Ya-Nan Qiao; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2022-05-25

Review 6.  Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Authors:  Mitchel Tate; Aaron Chong; Emma Robinson; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

7.  GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states.

Authors:  Gustavo J Hein; Chris Baker; Joanne Hsieh; Sarah Farr; Khosrow Adeli
Journal:  Diabetes       Date:  2012-10-01       Impact factor: 9.461

8.  The chylomicron: relationship to atherosclerosis.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  Int J Vasc Med       Date:  2011-10-05

9.  The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men.

Authors:  Karin M Slivkoff-Clark; Anthony P James; John Cl Mamo
Journal:  Nutr Metab (Lond)       Date:  2012-02-07       Impact factor: 4.169

10.  Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

Authors:  Pedro Valdivielso; José Rioja; Carlota García-Arias; Miguel Angel Sánchez-Chaparro; Pedro González-Santos
Journal:  Cardiovasc Diabetol       Date:  2009-01-08       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.